)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Karyopharm Therapeutics (KPTI) investor relations material
Karyopharm Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Nov, 2025
Executive summary
Achieved Q3 2025 total revenue of $44.0 million, up from $38.8 million in Q3 2024, driven by increased U.S. XPOVIO net product revenue and milestone-related license revenue.
Completed enrollment in the Phase 3 SENTRY trial for myelofibrosis, with top-line data expected in March 2026.
Reaffirmed full-year 2025 total revenue guidance of $140–$155 million and U.S. XPOVIO net product revenue guidance of $110–$120 million.
Cash runway extended into Q2 2026 following recent financing, but substantial doubt exists regarding ability to continue as a going concern without additional funding.
Focused on advancing late-stage clinical programs, driving XPOVIO franchise growth, and maintaining financial discipline.
Financial highlights
U.S. XPOVIO net product revenue was $32.0 million in Q3 2025, an 8.5% increase year-over-year.
License and other revenue reached $12.0 million, up nearly 30% year-over-year, mainly due to milestone payments.
R&D expenses decreased to $30.5 million; SG&A expenses down to $26.6 million.
Net loss for Q3 2025 was $33.1 million ($3.82 per share), with more than half due to non-cash items.
Cash, cash equivalents, and investments were $46.2 million as of September 30, 2025, with pro forma cash post-financing of $78 million.
Outlook and guidance
Full-year 2025 total revenue expected between $140 million and $155 million; U.S. XPOVIO net product revenue guidance set at $110–$120 million.
R&D and SG&A expenses projected to be $235–$245 million for 2025.
Liquidity expected to fund operations into Q2 2026, but additional capital will be required beyond that.
License and other revenue is expected to decrease in Q4 2025 due to lower milestone revenue.
Net product revenue and operating expenses are expected to remain consistent in Q4 2025 compared to Q3.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Karyopharm Therapeutics earnings date
Q4 202517 Feb, 2026
Next Karyopharm Therapeutics earnings date
Q4 202517 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage